Signature Healthcare At Tower Road Medicare and Medicaid Location: 26 Tower Rd, Marietta, Georgia 30060 Ratings: Phone: (770) 422-8913 |
Signature Healthcare Of Marietta Medicare and Medicaid Location: 811 Kennesaw Avenue, Marietta, Georgia 30060 Ratings: Phone: (770) 422-2451 |
Pruitthealth - Marietta Medicare and Medicaid Location: 70 Saine Drive Sw, Marietta, Georgia 30008 Ratings: Phone: (770) 429-8600 |
Manor Care Rehabilitation Center - Marietta Medicare and Medicaid Location: 4360 Johnson Ferry Place, Marietta, Georgia 30068 Ratings: Phone: (770) 971-5870 |
A.g. Rhodes Home, Inc - Cobb Medicare and Medicaid Location: 900 Wylie Road, Marietta, Georgia 30067 Ratings: Phone: (770) 427-8727 |
Autumn Breeze Health And Rehab Medicare and Medicaid Location: 1480 Sandtown Road Sw, Marietta, Georgia 30008 Ratings: Phone: (770) 422-1755 |
Roselane Health And Rehabilitation Center Medicare and Medicaid Location: 613 Roselane Street, Marietta, Georgia 30064 Ratings: Phone: (770) 792-9800 |
News Archive
The U.S. Food and Drug Administration (FDA) today issued a second emergency use authorization (EUA) to Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics Incorporated, for its 2009 H1N1 influenza virus test. With the EUA, Focus Diagnostics is the only company in the U.S. to offer test kits for detecting the pandemic 2009 H1N1 virus that the FDA has authorized for emergency use by CLIA high-complexity labs, which include certain hospital and regional labs.
Mothers' vitamin D levels at a gestation of 26 weeks or less were positively related to birth weight and head circumference, and, in the first trimester were negatively associated with risk of a baby being born small for gestational age, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.
Recently, researchers from the UK and Sweden used highly sensitive multiplexed immunohistochemistry to study the brain tissue of COVID-19 patients and controls to analyze ACE2 expression in brain pericytes of patients with neurological symptoms. They also used spatial immunophenotyping to assess inflammation in brain tissue of COVID-19 patients.
› Verified 5 days ago